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Introduction
Due to late presentation of symptoms, ovarian cancer is diagnosed at an 
advanced stage in most patients (1). Current standard of care for patients 
with advanced stage ovarian cancer consists of surgical debulking combined 
with paclitaxel and carboplatin for 6 cycles (2). Despite often aggressive 
surgery and high initial response rates, the majority of patients will relapse, 
with the length of the progression-free interval being a direct predictor of 
sensitivity to second-line platinum therapy (3-4). As a result, survival rates 
have not improved significantly over the last decades, with a 5-year survival 
rate of 19-28% in advanced stage disease (1).
A big leap in achieving upfront selection of ovarian cancer patients is the 
radical change in the definition of epithelial ovarian cancer, which is no longer 
conceived as one entity. It is now widely accepted that histological subtypes 
of ovarian cancer, i.e. high-grade serous, low-grade serous, endometrioid, 
mucinous and clear cell carcinoma, are derived via different pathways of 
tumorigenesis, divided in low-grade and high-grade pathways (5). Of these 
subtypes, high-grade serous ovarian cancer (HGSOC) is characterised by 
an almost ubiquitous presence of TP53 mutations (6). In addition in ~20% 
of the HGSOC cases, a mutation in BRCA1 or BRCA2 is found, predisposing 
these women to hereditary breast and ovarian cancer. Remarkably, hardly 
any other gene mutations are found in HGSOC (6). In striking contrast, a 
remarkable degree of copy number aberrations and genomic instability is 
present, suggesting disruption of DNA repair pathways during early tumour 
development (7). 
The different histological subtypes are known for their distinct platinum-
sensitivity. The majority of HGSOC patients respond to first-line platinum-
based chemotherapy, whereas clear cell, mucinous and low-grade serous 
tumours are reported to be more resistant (8-9). Especially HGSOC patients 
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harbouring a BRCA1 or BRCA2 mutation are described to be sensitive towards 
platinum-based chemotherapy with a significant better response rate and 
longer survival (10). BRCA1 and BRCA2 are both important players in the error-
free homologues recombination (HR) repair pathway, which repairs double 
strand DNA breaks and stalled replication forks. A novel type of anti-cancer 
agents, Poly(ADP)ribose polymerase (PARP) inhibitors (PARPi), take advantage 
of defects in the HR repair pathway. By inhibiting the repair of single strand 
DNA breaks in a HR deficient background, treatment with PARPi results in 
double strand breaks, thus causing so-called “synthetic lethality”. In BRCA1/2 
mutation carriers these agents have already shown promising results (11-12). 
Inhibitors of other DNA damage repair pathway components are increasingly 
under investigation for their potential to enhance effectiveness of current 
standard cancer treatments such as radiotherapy and chemotherapy (13).
Furthermore, targeting the anti-immune response of the tumour has recently 
gained much interest, for instance via blocking immune checkpoints such as 
programmed death-ligand 1 (PDL-1) (14). For quite some time, pro-apoptotic 
members of the tumour necrosis factor (TNF) family have been studied 
in ovarian cancer, for instance tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) and its receptors. One of the other TNF family 
members currently under investigation is CD70, ligand of the co-stimulatory 
TNF receptor superfamily member CD27 and transiently expressed on antigen- 
activated T and B-lymphocytes. Interestingly, in haematological cancers and 
in several solid cancers like melanoma, glioblastoma, renal cell-, pancreatic-, 
lung- and ovarian cancer, aberrant CD70 expression has been reported 
(15). As the role of CD70 in ovarian cancer has hardly been described and 
its importance is yet unknown, the characterisation of CD70 is warranted 
to investigate its function and its potential as a therapeutic target in ovarian 
cancer.
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In the search for new targets and biomarkers, patient-tailored therapy, based 
on a patient’s individual tumour characteristics, is widely considered as the 
next step in improving outcome, decreasing side effects and overcoming 
resistance (16). However, given the intertumoral, but also intratumoral 
heterogeneity of HGSOC, only subsets of patients will be likely to benefit from 
targeted therapies. Therefore, more representative experimental models 
are an important step in improving bench-to-bedside translation (17). The 
aim of this thesis is to obtain a better understanding of factors determining 
response to therapy in HGSOC patients by integrating multiple in vitro and 
newly established in vivo models. This thesis describes preclinical work on 
predictive biomarkers in the DNA damage response pathway as well as in the 
TNF family pathway, suitable for upfront selection of patients and as targets 
for innovative therapy. Furthermore, the development of an ovarian cancer 
patient-derived xenograft mouse model is extensively described, as well as 
the possible translational value of this model.
Outline of the thesis
In the past decades much progress has been made in developing representative 
ovarian cancer models using both in vitro and in vivo approaches that mimic 
ovarian cancer pathogenesis, tumour microenvironment, angiogenesis and 
therapy response (18). In Chapter 2, we review recently developed preclinical 
ovarian cancer models suitable for investigating response to platinum-based 
chemotherapy and biomarker-based personalised strategies to overcome 
platinum-based chemo-resistance. Finally, as an example of integration of 
several of these models, we discuss current studies on PARPi in BRCA1/2-
mutation carriers and sporadic ovarian cancer patients displaying a so-called 
BRCAness phenotype.
The effectiveness of conventional DNA damaging chemotherapeutics is 
limited by DNA damage checkpoints and DNA repair mechanisms that 
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protect tumour cells from DNA damage-induced cell death. As part of the 
DNA damage response (DDR), the Ataxia Telangiectasia Mutated (ATM) 
signalling axis has drawn attention as a possible new target in enhancing 
the cytotoxic effectiveness of radiotherapy and chemotherapy. In Chapter 3, 
we immunohistochemically analyse the expression of several downstream 
targets in the ATM signalling pathway, using tumour tissue from a well-
defined subset of advanced stage HGSOC patients. To explore the cell 
biological basis for high Chk2 expression being related to a good response 
to therapy, we subsequently study the effects of modulating Chk2 levels in 
vitro and investigate its effects on cisplatin sensitivity in two ovarian cancer 
cell lines.
Besides damage repair capacity, targeting anti-immune responses of 
tumours has also gained interest as a way of improving treatment outcomes. 
In Chapter 4, we evaluate CD70 expression levels in a large panel of ovarian 
cancer cell lines and investigate the relation of CD70 with cisplatin sensitivity. 
Furthermore, after having observed a CD70 splicing variant, CD70isoform 
(CD70iso), we investigate the cell surface expression of both CD70 variants. 
To study their functional significance, we transfect CD70-negative Chinese 
hamster ovary (CHO) cells with CD70wt or CD70iso and investigate their 
influence on peripheral blood mononuclear cell (PBMC) proliferation.
Patient-derived xenografts (PDXs) are increasingly considered as authentic 
preclinical models for studying ovarian cancer as they reflect heterogeneity of 
the original tumour and preserve response to therapy. However, using PDXs 
for preclinical cancer research demands proper storage of tumour material 
to facilitate logistics and to reduce the number of animals needed. In Chapter 
5, we present our panel of ovarian cancer PDXs. Furthermore, we carefully 
compare two methods for biobanking of PDX tumour material: A fetal calf 
serum (FCS)-based “FCS/DMSO” freezing protocol and a low serum-based 
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“vitrification” protocol. We analyse and compare both methods in terms of 
take- and growth rate and resemblance to the parental tumour from the 
patient, using immunohistochemistry and copy number alterations. 
A number of therapeutic targets are currently being explored for the treatment 
of ovarian cancer, such as vascular endothelial growth factor (VEGF) and 
insulin-like growth factor-1 receptor (IGF-1R). Development of non-invasive 
methods for detection of multiple tumour-related proteins in patients would 
certainly assist the selection of targeted therapies and monitoring early 
responses in individual patients. In Chapter 6, we test the feasibility of dual 
wavelength near-infrared fluorescence (NIRF) imaging in multiple ovarian 
cancer PDXs, using the monoclonal antibodies bevacizumab (anti-VEGF) and 
MAB391 (anti-IGF-1R) coupled to the NIRF dyes IRDye-800CW and IRDye-
680RD, respectively. Furthermore, using this technique, we monitor the in 
vivo expression of VEGF and IGF-1R during treatment with cisplatin. 
Finally, a summary of the results described in this thesis is presented in 
Chapter 7, along with a general discussion and future perspectives.
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